... or 24 mg/day, was demonstrated to be as safe and effective for the treatment of mild to moderate AD. Alzheimer’s disease Cholinesterase inhibitors Prolonged-release formulation Galantamine Nicotinic receptors © 2005 S. Karger AG, Basel 2005 Copyright / Drug Dosage / Disclaimer...

...), or to mimic the effects of ACh (nicotinic agonists) by acting directly on nicotinic receptors. Clinical studies suggest that AChE inhibitors produce only short-term symptomatic improvement. Similarly, long-term use of nicotinic agonists may induce desensitization of nicotinic receptors, leading to tolerance...

... W Nicotinic receptors W Acetylcholinesterase inhibition Abstract Galantamine, a novel treatment for Alzheimer s disease (AD), has a dual mechanism of action, combining allosteric modulation of nicotinic acetylcholine receptors with reversible, competitive inhibition of acetylcholinesterase...

..., may shift this balance in favor of positive effects. Nerve growth factor Alzheimer’s disease Cognitive deficits Electroencephalography Positron emission tomography Pain Weight loss Nicotinic receptors Original Research Article Dement Geriatr Cogn Disord 1998;9:246 257 Accepted: January 1...

... and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements. Imaging PET Alzheimer's disease Neuroreceptor Muscarinic receptors Nicotinic receptors Tacrine Dementia...